Innovators Hour: Aaron DiAntonio MD, PhD
Date
Nov 19
Time
4:30pm - 6:30pm
Where
BioSTL Building, 4340 Duncan Ave, St. Louis, MO
Host
BioSTL
Price
Free-Registration is required
About this Event
Dr. DiAntonio is a leading researcher on neural circuits and the molecular pathways that control axonal degeneration. Co-founded with Dr. Jeff Milbrandt, Disarm Therapeutics developed drug candidates for neurodegenerative diseases by targeting SARM1, a key enzyme controlling axonal degeneration.
With proof of concept funding from WashU OTM and BioGenerator and venture backing from Atlas Ventures, Lightstone Ventures, and AbbVie Ventures, Disarm Therapeutics was acquired by Eli Lilly in 2020 enabling its discoveries to reach clinical trials. Dr. DiAntonio has since gone on to found additional companies built on their research.
Join us to learn more from Dr. DiAntonio about moving from bench science to building companies, what it takes to commercialize a discovery in St. Louis, and what he has learned along the way.